Stephen Hsieh, MD
Internal Medicine · Lexington, NCNPI 1982664678
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 997 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 10.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,584 and has fallen 54.4% since, to $1,633 in 2025. Among internal medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 997 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$2K
- AstraZeneca$1K
- Pfizer$1K
- Lilly USA, LLC$1K
- GSK$826
- plus $9K from 54 others
What the payments were for
- Food & beverage$16,68399%
- Education$1381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$235
- FARXIGA$228
- Kerendia$220
- BPRO BT AMBULATORY BLOOD PRESSURE MONITORING SYSTEM$182
- NURTEC ODT$168
- SYMBICORT$127
- PULMICORT RESPULES$127
- BREZTRI$123
- ZAVZPRET$102
- LUCEMYRA$100
How this compares
$16,821 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 120 | $139,843 |
| JardianceEmpagliflozin | 110 | $100,454 |
| CreonLipase/Protease/Amylase | 20 | $81,224 |
| EliquisApixaban | 92 | $62,810 |
| RybelsusSemaglutide | 42 | $59,648 |
| OzempicSemaglutide | 63 | $59,069 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $56,522 |
| FarxigaDapagliflozin Propanediol | 76 | $55,121 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $42,051 |
| VraylarCariprazine Hcl | 28 | $41,543 |
| LinzessLinaclotide | 57 | $38,174 |
| XareltoRivaroxaban | 30 | $38,091 |
| Xtampza ErOxycodone Myristate | 59 | $35,777 |
| JanuviaSitagliptin Phosphate | 38 | $29,103 |
| TrulicityDulaglutide | 17 | $25,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Vraylar, Linzess, Qulipta | $1,543 | $174,126117 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,194 | $174,118159 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $584 | $143,080170 claims |
| Novo NordiskRybelsus, Ozempic | $1,724 | $118,717105 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,489 | $103,987164 claims |
| PfizerEliquis | $1,260 | $62,81092 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $826 | $61,65887 claims |
| MerckJanuvia, Janumet, Janumet Xr | $359 | $43,35063 claims |
| Johnson & JohnsonXarelto | $96 | $38,09130 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $392 | $21,19941 claims |
| Astellas Pharma US IncMyrbetriq | $501 | $18,77242 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $40 | $18,52612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Lexington
- Nirmish ShahDurham$862K
- Eugene WrightFayetteville$839K
- Saad UsmaniCharlotte$551K
- Bhakti PaulRaleigh$536K
- Mary KlotmanDurham$478K
- Manesh PatelDurham$435K
- Millie LongChapel Hill$374K
- Marc JohnsonCharlotte$342K
- Christina CraterRaleigh$330K
- Jamy ArdWinston Salem$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.